Dermapharm Holding SE (DMP.DE)

EUR 37.6

(-0.4%)

Long Term Debt Summary of Dermapharm Holding SE

Dermapharm Holding SE's latest annual long term debt in 2023 was 950.7 Million EUR , up 85.84% from previous year.
Dermapharm Holding SE's latest quarterly long term debt in 2024 Q2 was 948.52 Million EUR , up 3.2% from previous quarter.
Dermapharm Holding SE reported annual long term debt of 511.56 Million EUR in 2022, down -10.99% from previous year.
Dermapharm Holding SE reported annual long term debt of 574.72 Million EUR in 2021, down -1.04% from previous year.
Dermapharm Holding SE reported quarterly long term debt of 948.52 Million EUR for 2024 Q2, up 3.2% from previous quarter.
Dermapharm Holding SE reported quarterly long term debt of 1.05 Billion EUR for 2023 Q2, down -5.95% from previous quarter.

Annual Long Term Debt Chart of Dermapharm Holding SE (2023 - 2013)

Historical Annual Long Term Debt of Dermapharm Holding SE (2023 - 2013)

Year	Long Term Debt	Long Term Debt Growth
2023	950.7 Million EUR	85.84%
2022	511.56 Million EUR	-10.99%
2021	574.72 Million EUR	-1.04%
2020	580.75 Million EUR	6.89%
2019	543.34 Million EUR	133.45%
2018	232.74 Million EUR	4.61%
2017	222.48 Million EUR	129.61%
2016	96.89 Million EUR	-35.86%
2015	151.07 Million EUR	-6.47%
2014	161.53 Million EUR	60.2%
2013	100.83 Million EUR	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q1	919.12 Million EUR	-3.32%
2024 Q2	948.52 Million EUR	3.2%
2023 Q2	1.05 Billion EUR	-5.95%
2023 Q3	1.03 Billion EUR	-1.74%
2023 FY	950.7 Million EUR	85.84%
2023 Q1	1.11 Billion EUR	118.79%
2023 Q4	950.7 Million EUR	-8.09%
2022 Q2	575.31 Million EUR	-0.09%
2022 Q4	511.56 Million EUR	-11.15%
2022 FY	511.56 Million EUR	-10.99%
2022 Q1	575.81 Million EUR	0.19%
2022 Q3	575.78 Million EUR	0.08%
2021 Q1	579.78 Million EUR	-0.17%
2021 FY	574.72 Million EUR	-1.04%
2021 Q4	574.72 Million EUR	-0.16%
2021 Q3	575.63 Million EUR	-0.18%
2021 Q2	576.66 Million EUR	-0.54%
2020 Q2	602.25 Million EUR	10.77%
2020 Q4	580.75 Million EUR	-3.44%
2020 Q1	543.69 Million EUR	0.06%
2020 Q3	601.45 Million EUR	-0.13%
2020 FY	580.75 Million EUR	6.89%
2019 Q3	451.03 Million EUR	3.24%
2019 FY	543.34 Million EUR	133.45%
2019 Q1	238.13 Million EUR	2.32%
2019 Q2	436.86 Million EUR	83.45%
2019 Q4	543.34 Million EUR	20.47%
2018 Q2	218.77 Million EUR	-1.07%
2018 FY	232.74 Million EUR	4.61%
2018 Q4	232.74 Million EUR	-16.26%
2018 Q3	277.94 Million EUR	27.04%
2018 Q1	221.15 Million EUR	-0.6%
2017 Q4	222.48 Million EUR	-5.49%
2017 Q3	235.39 Million EUR	0.0%
2017 Q1	- EUR	-100.0%
2017 FY	222.48 Million EUR	129.61%
2016 FY	96.89 Million EUR	-35.86%
2016 Q4	96.89 Million EUR	0.0%
2015 FY	151.07 Million EUR	-6.47%
2014 FY	161.53 Million EUR	60.2%
2013 FY	100.83 Million EUR	0.0%

Peer Long Term Debt Comparison of Dermapharm Holding SE

Name	Long Term Debt	Long Term Debt Difference
MPH Health Care AG	8.33 Million EUR	-11308.46%
Apontis Pharma AG	6 Million EUR	-15745.083%
Evotec SE	477.11 Million EUR	-99.262%
MERCK Kommanditgesellschaft auf Aktien	8.84 Billion EUR	89.253%
PharmaSGP Holding SE	65.37 Million EUR	-1354.345%
SynBiotic SE	2.89 Million EUR	-32757.2%